ARROWHEAD PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $2.00 million for the 12-month period ending 2009-09-30, per its 10-Q filed 2014-05-06.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2014-05-06
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2009-09-30 | $2.00M 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |